Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
Open Access
- 1 May 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (9) , 2785-2795
Abstract
Purpose: The epidermal growth factor receptor (EGFR) is highly expressed in many human soft tissue sarcomas (STS). However, EGFR blockade has not apparently been used for human STS therapy; therefore, we examined the in vitro and in vivo effects and the underlying mechanisms before considering EGFR blockade as a therapy for STS patients.Keywords
This publication has 43 references indexed in Scilit:
- Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the PathwayClinical Cancer Research, 2006
- Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitorsProceedings of the National Academy of Sciences, 2006
- Expression of HER1/EGFR protein in human soft tissue sarcomasEuropean Journal of Surgical Oncology, 2006
- Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude MiceClinical Cancer Research, 2006
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal AdenocarcinomaJournal of Clinical Oncology, 2005
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract CancersClinical Cancer Research, 2004
- Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 casesJournal of Cancer Research and Clinical Oncology, 2002
- ZD1839: targeting the epidermal growth factor receptor in cancer therapyExpert Opinion on Investigational Drugs, 2002
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000